Gefitinib, a tyrosine kinase inhibitor (TKI) that targets EGFR, is a first-line chemotherapeutic drug for treating NSCLC, particularly in patients with EGFR mutations [32,33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.